Bio-Mimetic Hormone Replacement Therapy

In the field of menopause medicine over the last century, women and medical experts have been used to discussing about bio-identical hormone replacement therapy. While this is great, the issue lies in the terminology itself. In reality, you cannot replace your hormones. Hormones can be copied.. In menopause medicine, we have all gotten used to discussing about bio-identical hormone replacement therapy or BHRT. The truth, however, is that hormones cannot be replaced - in this sense, they're not really bio-identical. Instead, they can only be mimicked and restored.

The latest treatment for menopausal is multi-phasic rhythmic dosing of bio-mimetic hormone replacement therapy (BHRT) which utilizes natural hormones in a bio-mimetic way In the United States, more than two million women are using this type of treatment for menopause. "Natural hormones are not bio-mimedic unless the body can recognize them as hormones, and they are not considered restoration unless what has been lost is truly restored," said Author T.S. Wiley.

A question is presented: would the symptoms of aging disappear if bio-mimedic hormones are dosed to imitate the normal rise and fall of the hormone levels in menstrual cycle of a young woman? Today, however, a standard for compounded bio-identical hormone replacement protocol is non-existent. However, she has created a registered pharmacy system to circumvent the current lack of legality and availability of bio-mimetic, currently known as bio-identical hormones, for testing and study.

Moreover, a new research is underway at the University of Texas and its multi-phasic physiologic dosing will be referred to as Bioidentical Hormones On Trial, or B.H.O.T., a comparison of patterns of administration and dosing of compounded bio-identical hormone therapy (BHT). This research will be the first of its kind to trace and quantify outcomes based on dosing and patterns of administration of BHT. The main goal of the research will be to examine clinical outcomes and quality of life indicators of patients receiving BHT at 10 to 12 primary care provider's practices.

The results of the research will be utilized to help establish which dosage and pattern of BHT administration is most effective. Results will be used to come up with a prospective, randomized clinical trial with the objective of standardizing BHT dosing and administration patterns.

This research, whose participants are women between the ages of 35 and 60 who are current users of compounded bioidentical hormone therapy (BHT), is an observational one. Clinical care of the respondents won't be altered as a result of participation in the study. The study will have a timeline of 3 years. Quality of life, symptom relief and impact of BHT on physical health like breast, endometrial and cardiovascular measures are among the variables that will be examined in this research.

Furthermore, the results of the research will be presented nationally and internationally, and they'll be submitted for publication in various women's and medical journals. Once again, the results of the study will be utilized to come up with a standardized BHT dosing and patterns of administration.

Among the main goals of the research are: (1) to evaluate the quality of life indicators of the patients who are currently receiving BHT at 10-12 practices of primary care providers (2) to check the effectiveness, safety and overall quality of life of respondents who are using 1 among 3 dosing patterns (3)to monitor the women's laboratory results (4) to track the adverse effects experienced by the respondents in relation to bioidentical hormone replacement therapy and (5) to measure up the compounding pharmacies' compliance to the standards.